Soo Park, MD
Hematology & Oncology · la Jolla, CANPI 1821351198
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,638 of the $32,831 with a category attached, or 81.1%. 13 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 56.6% of the total. 2025 is the largest year on record at $24,556, more than ten times the $967 reported in 2019.
Across 65 payments — averaging $505.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$19K
- Regeneron$5K
- Regeneron Healthcare Solutions, Inc.$4K
- Sanofi$3K
- Genentech, Inc.$845
- E.r. Squibb & Sons, L.L.C.$656
- plus $577 from 7 others
Across 146 payments — averaging $6988.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$375K
- Regeneron$321K
- Merck$258K
- Genentech, Inc.$35K
- Exelixis Inc.$32K
What the payments were for
- Consulting fees$26,63881%
- Travel & lodging$2,4698%
- Food & beverage$3,72411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 18 | $18,595 |
| Regeneron | 11 | $4,984 |
| Regeneron Healthcare Solutions, Inc. | 10 | $4,362 |
| Sanofi | 6 | $2,811 |
| Genentech, Inc. | 4 | $845 |
| E.r. Squibb & Sons, L.L.C. | 7 | $656 |
| Karyopharm Therapeutics Inc. | 1 | $125 |
| GSK | 1 | $121 |
| Astellas Pharma US Inc | 1 | $109 |
| AstraZeneca | 2 | $83 |
| Immunocore Limited | 1 | $61 |
| Merck | 2 | $42 |
| Iovance Biotherapeutics, Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$11,358
- Unloxcyt$9,268
- LEVULAN KERASTICK$8,813
- Non-Covered Product$845
- OPDIVO$298
- SARCLISA$230
- XPOVIO$125
- ELITEK$121
- BLENREP$121
- Vyloy$109
How this compares
$32,831 in reported general payments places this provider in the 80th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in la Jolla
- Alan Savenla Jolla$323K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.